sub:assertion {
  d:DB00958 dv:ddi-interactor-in dr:DB00958_DB01097 .
  d:DB01097 dv:ddi-interactor-in dr:DB00958_DB01097 .
  dr:DB00958_DB01097 dct:identifier "drugbank_resource:DB00958_DB01097" ;
    dct:title "DDI between Carboplatin and Leflunomide - Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Carboplatin and Leflunomide - Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.  [drugbank_resource:DB00958_DB01097]"@en .
}